Article
Clinical Neurology
Marja Niiranen, Aleksi Kontkanen, Olli Jaaskelainen, Hanna-Mari Tertsunen, Tuomas Selander, Paivi Hartikainen, Nadine Huber, Eino Solje, Annakaisa Haapasalo, Tarja Kokkola, Tarja Lohioja, Sanna-Kaisa Herukka, Sakari Simula, Anne M. Remes
Summary: The study found significantly elevated serum GFAP levels in both BRRMS and ARRMS patients compared to healthy controls, with no significant differences between BRRMS and ARRMS. There were also no significant differences in serum NfL levels among the groups.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Article
Clinical Neurology
Carlos Camara-Lemarroy, Claudia Silva, Jit Gohill, V. Wee Yong, Marcus Koch
Summary: In this cohort of patients with inactive PPMS, HCQ treatment attenuated the increase of NfL and GFAP after 6 months of treatment and up to 18 months of follow-up, suggesting a treatment effect of HCQ over these biomarkers. RNFL thickness, a marker of neuroaxonal atrophy, was associated with disability worsening and should be explored further as a prognostic marker in this population.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Pablo Arroyo Pereiro, Albert Munoz-Vendrell, Isabel Leon Moreno, Laura Bau, Elisabet Matas, Lucia Romero-Pinel, Antonio Martinez Yelamos, Sergio Martinez Yelamos, Pol Andres-Benito
Summary: This study investigates the potential role of serum biomarkers in long-term prognostication of multiple sclerosis, and suggests that serum neurofilament light chain levels may serve as a promising marker for long-term disability.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Nicolas Fissolo, Pascal Benkert, Jaume Sastre-Garriga, Neus Mongay-Ochoa, Andreu Vilaseca-Jolonch, Sara Llufriu, Yolanda Blanco, Harald Hegen, Klaus Berek, Francisco Perez-Miralles, Konrad Rejdak, Luisa M. Villar, Enric Monreal, Roberto Alvarez-Lafuente, Onder K. Soylu, Ahmed Abdelhak, Franziska Bachhuber, Hayrettin Tumani, Sergio Martinez-Yelamos, Antonio J. Sanchez-Lopez, Antonio Garcia-Merino, Lucia Gutierrez, Tamara Castillo-Trivino, Jan Lycke, Igal Rosenstein, Roberto Furlan, Massimo Filippi, Nieves Tellez, Lluis Ramio-Torrenta, Jan D. Lunemann, Heinz Wiendl, Sara Eichau, Michael Khalil, Jens Kuhle, Xavier Montalban, Manuel Comabella
Summary: This study aimed to investigate the potential of serum biomarker levels in predicting disability progression in patients with primary progressive multiple sclerosis (PPMS). The study found that levels of neurofilament light chain (sNfL), glial fibrillar acidic protein (sGFAP), and chitinase 3-like 1 (sCHI3L1) were associated with changes in the Expanded Disability Status Scale (EDSS) over different time periods.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Clinical Neurology
Manuel Comabella, Jaume Sastre-Garriga, Pere Carbonell-Mirabent, Nicolas Fissolo, Carmen Tur, Sunny Malhotra, Deborah Pareto, Francesc X. Aymerich, Jordi Rio, Alex Rovira, Mar Tintore, Xavier Montalban
Summary: This study found that serum neurofilament light chain (sNfL) levels can be used as a prognostic biomarker for future long-term disability progression in patients with progressive multiple sclerosis (MS).
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Article
Clinical Neurology
Carlos Camara-Lemarroy, Luanne Metz, Jens Kuhle, David Leppert, Eline Willemse, David K. B. Li, Anthony Traboulsee, Jamie Greenfield, Graziela Cerchiaro, Claudia Silva, V. Wee Yong
Summary: This study assessed the value of blood NfL and GFAP as biomarkers of disease activity in minocycline-treated patients with CIS. Results showed that NfL levels were associated with disease activity, while GFAP levels were correlated with lesion volume. Minocycline treatment increased NfL levels and decreased GFAP and MMP-7 levels.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Medicine, General & Internal
Timo Uphaus, Falk Steffen, Muthuraman Muthuraman, Nina Ripfel, Vinzenz Fleischer, Sergiu Groppa, Tobias Ruck, Sven G. Meuth, Refik Pul, Christoph Kleinschnitz, Erik Ellwardt, Julia Loos, Sinah Engel, Frauke Zipp, Stefan Bittner
Summary: This study found that sNfL levels at baseline predict relapse-free disability progression in patients with multiple sclerosis, and further discriminates patients with secondary progressive MS (SPMS) at follow-up.
Article
Clinical Neurology
Maureen van Dam, Brigit A. de Jong, Eline A. J. Willemse, Ilse M. Nauta, Marijn Huiskamp, Martin Klein, Bastiaan Moraal, Sanne de Geus-Driessen, Jeroen J. G. Geurts, Bernard M. J. Uitdehaag, Charlotte E. Teunissen, Hanneke E. Hulst
Summary: This study investigated the use of multimodal (bio)markers in predicting cognitive functioning in people with MS (PwMS). The study found that levels of neurofilament light chain (NfL) in both serum and cerebrospinal fluid (CSF) were correlated with processing speed. The combination of grey matter volume (NGMV) and serum NfL (sNfL) performed the best as a multimodal marker in predicting cognitive status.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
C. Ammitzboll, T. B. Dyrby, L. Bornsen, K. Schreiber, R. Ratzer, J. Romme Christensen, P. Iversen, M. Magyari, H. Lundell, P. E. H. Jensen, P. S. Sorensen, H. R. Siebner, F. Sellebjerg
Summary: This study investigated the relationship between serum concentrations of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) and disease activity and severity in progressive multiple sclerosis (MS). The results showed that serum concentrations of NfL and GFAP were higher in progressive MS patients compared to healthy controls, and serum NfL was correlated with the EDSS score. Regression analyses revealed that high serum NfL was independently associated with decreased fractional anisotropy (FA) and increased mean diffusivity (MD) in normal-appearing white matter (NAWM), while high serum GFAP was independently associated with decreased MD in NAWM and decreased MD and increased FA in cortical gray matter (CGM).
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Biochemistry & Molecular Biology
Christoph Kessler, Christoph Ruschil, Ahmed Abdelhak, Carlo Wilke, Aleksandra Maleska, Jens Kuhle, Markus Krumbholz, Markus C. Kowarik, Rebecca Schuele
Summary: This study found that levels of NfL were significantly increased in PPMS patients compared to SPG4, and there was a trend towards higher levels of sGFAP in PPMS. However, due to overlapping values in both groups, these biomarkers were not useful for differentiating between PPMS and HSP.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Clinical Neurology
Simon Thebault, Michael Reaume, Roberto Furlan, Alice Laroni, Antonio Uccelli, Mark S. Freedman, Ruth Ann Marrie, James J. Marriot, Ronald A. Booth
Summary: This study assessed the association between longitudinal changes in neurofilament light chain (sNfL) and future relapses in multiple sclerosis (MS), finding that long-term increases in sNfL levels were associated with an increased risk of relapse, especially in patients with lower baseline sNfL. These results help identify patients who would benefit from early treatment optimization.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Clinical Neurology
Kathryn C. Fitzgerald, Elias S. Sotirchos, Matthew D. Smith, Hannah-Noelle Lord, Anna DuVal, Ellen M. Mowry, Peter A. Calabresi
Summary: This study aimed to assess the effects of demographics, lifestyle factors, and comorbidities on serum neurofilament light chain (sNfL) levels in individuals without neurologic disease and establish population-specific reference ranges for sNfL. The study analyzed data from the National Health and Nutrition Examination Survey (NHANES) and found that age, creatinine, and glycosylated hemoglobin (HbA1c) were the best predictors of sNfL levels. The results provide guidance for interpreting sNfL levels in relation to neurologic conditions.
ANNALS OF NEUROLOGY
(2022)
Article
Clinical Neurology
Ahmed Abdelhak, Kai Antweiler, Markus C. Kowarik, Makbule Senel, Joachim Havla, Uwe K. Zettl, Ingo Kleiter, Thomas Skripuletz, Axel Haarmann, Alexander Stahmann, Andre Huss, Stefan Gingele, Markus Krumbholz, Pascal Benkert, Jens Kuhle, Tim Friede, Albert C. Ludolph, Ulf Ziemann, Tania Kuempfel, Hayrettin Tumani
Summary: This study confirms the value of serum GFAP and NfL in PPMS and SPMS, and indicates that the combination of high GFAP and low NfL levels can help identify progression risk in people with progressive multiple sclerosis.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2023)
Article
Clinical Neurology
Dimitrios C. Ladakis, Maria Reyes-Mantilla, Sachin P. Gadani, Jackson W. Mace, Susana C. Dominguez-Penuela, Mayaa J. Appiah, Matthew D. Smith, Pavan Bhargava, Robert J. Fox, Shiv Saidha, Peter A. Calabresi
Summary: This study found that serum MIF levels were associated with brain atrophy in male PPMS patients, but not in SPMS patients. Ibudilast did not affect MIF levels.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Kristin Galetta, Chinmay Deshpande, Brian C. Healy, Bonnie Glanz, Marina Ziehn, Shrishti Saxena, Anu Paul, Fermisk Saleh, Mikaela Collins, Patricia Gaitan-Walsh, Paola Castro-Mendoza, Howard L. Weiner, Tanuja Chitnis
Summary: In practice, serum neurofilament light is associated with health outcomes and healthcare utilization in multiple sclerosis patients.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2021)
Article
Clinical Neurology
Christian Barro, Brian C. Healy, Shrishti Saxena, Bonnie Glanz, Anu Paul, Mariann Polgar-Turcsanyi, Charles R. G. Guttmann, Rohit Bakshi, Howard L. Weiner, Tanuja Chitnis
Summary: This study suggests that serum neurofilament light chain (sNfL) levels are associated with cognitive decline in multiple sclerosis (MS) patients and can predict cognitive impairment, especially in active patients. However, serum glial fibrillary acidic protein (sGFAP) is not associated with cognitive function.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Clinical Neurology
Stephanie Meier, Eline A. J. Willemse, Sabine Schaedelin, Johanna Oechtering, Johannes Lorscheider, Lester Melie-Garcia, Alessandro Cagol, Muhamed Barakovic, Riccardo Galbusera, Suvitha Subramaniam, Christian Barro, Ahmed Abdelhak, Simon Thebault, Lutz Achtnichts, Patrice Lalive, Stefanie Muller, Caroline Pot, Anke Salmen, Giulio Disanto, Chiara Zecca, Marcus D'Souza, Annette Orleth, Michael Khalil, Arabella Buchmann, Renaud Du Pasquier, Ozgur Yaldizli, Tobias Derfuss, Klaus Berger, Marco Hermesdorf, Heinz Wiendl, Fredrik Piehl, Marco Battaglini, Urs Fischer, Ludwig Kappos, Claudio Gobbi, Cristina Granziera, Claire Bridel, David Leppert, Aleksandra Maleska Maceski, Pascal Benkert, Jens Kuhle
Summary: This study found that serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) are correlated with features of disease progression in multiple sclerosis (MS) and can predict disease progression. sGFAP may serve as a useful biomarker for disease progression in MS in individual patient management and drug development.
Article
Immunology
Alicia Gonzalez-Martinez, Rohit Patel, Brian C. Healy, Hrishikesh Lokhande, Anu Paul, Shrishti Saxena, Mariann Polgar-Turcsanyi, Howard L. Weiner, Tanuja Chitnis
Summary: This study aimed to evaluate serum miRNAs as biomarkers of No Evidence of Disease Activity (NEDA-3) at 2 years in patients with relapsing remitting MS (RRMS) treated with fingolimod. The results showed that miR-548a-3p expression levels at 6 months after fingolimod start were associated with NEDA-3 at 2 years in MS patients. This study provides class III evidence for the use of miR-548a-3p as a biomarker of NEDA-3 in fingolimod-treated patients.
JOURNAL OF NEUROINFLAMMATION
(2023)
Article
Immunology
Alicia Gonzalez-Martinez, Gauruv Bose, Hrishikesh Lokhande, Shrishti Saxena, Brian C. Healy, Mariann Polgar-Turcsanyi, Howard L. Weiner, Tanuja Chitnis
Summary: miR-320b and miR-25-3p expression are early biomarkers associated with MS severity and brain atrophy. This study suggests that miR-320b and miR-25-3p may serve as potential indicators for early diagnosis and treatment decisions in multiple sclerosis.
JOURNAL OF NEUROINFLAMMATION
(2023)
Article
Clinical Neurology
Gauruv Bose, Brian C. Healy, Shrishti Saxena, Fermisk Saleh, Anu Paul, Christian Barro, Hrishikesh A. Lokhande, Mariann Polgar-Turcsanyi, Mark Anderson, Bonnie I. Glanz, Charles R. G. Guttmann, Rohit Bakshi, Howard L. Weiner, Tanuja Chitnis
Summary: Current predictive models based on clinical and imaging characteristics can help with early risk-stratification in multiple sclerosis. Serum biomarkers, such as sNfL and sGFAP, provide additional information about subclinical disease activity and can improve the accuracy of predictive models for clinical and MRI outcomes.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Clinical Neurology
Sarah Conway, Shrishti Saxena, Clare Baecher-Allan, Rajesh Krishnan, Maria Houtchens, Bonnie Glanz, Taylor J. Saraceno, Mariann Polgar-Turcsanyi, Gauruv Bose, Rohit Bakshi, Shamik Bhattacharyya, Kristin Galetta, Tamara Kaplan, Christopher Severson, Tarun Singhal, Lynn Stazzone, Jonathan Zurawski, Anu Paul, Howard L. Weiner, Brian C. Healy, Tanuja Chitnis
Summary: This study assessed the antibody and T cell responses in multiple sclerosis (MS) patients and healthy controls (HCs) after 2 and 3 doses of SARS-CoV-2 mRNA vaccine. The results showed that after 2 doses, the seroconversion rate was lower in ocrelizumab and fingolimod groups compared to the HC group. After 3 doses, the seroconversion rate was lower in the ocrelizumab group and higher in the fingolimod group and HC group. Overall, MS patients had preserved cellular immune responses but attenuated antibody responses after vaccination.
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL
(2023)
Article
Immunology
Tanuja Chitnis, John Foley, Carolina Ionete, Nabil K. El Ayoubi, Shrishti Saxena, Patricia Gaitan-Walsh, Hrishikesh Lokhande, Anu Paul, Fermisk Saleh, Howard Weiner, Ferhan Qureshi, Michael J. Becich, Fatima Rubio da Costa, Victor M. Gehman, Fujun Zhang, Anisha Keshavan, Kian Jalaleddini, Ati Ghoreyshi, Samia J. Khoury
Summary: An 18-protein MS disease activity test was validated and showed improved performance compared to a single-protein model. The test was based on associations between algorithm scores and clinical/radiographic assessments. It can be used as a quantitative tool to enhance the care of MS patients.
CLINICAL IMMUNOLOGY
(2023)
Article
Immunology
Osman Corbali, Shrishti Saxena, Rohit Patel, Hrishikesh Lokhande, Tanuja Chitnis
Summary: This study investigated the activation mechanisms of CD4 T cells in pediatric MOGAD patients and healthy controls, and found that the NF-xB and STAT3 pathways play important roles in MOGAD. IL6 stimulation resulted in higher phosphorylation levels of STAT3 in certain CD4 T cell subsets of MOGAD patients. These findings provide potential targets for the treatment of MOGAD.
JOURNAL OF NEUROIMMUNOLOGY
(2023)
Article
Clinical Neurology
Gauruv Bose, Brian C. Healy, Christian Barro, Vanessa F. Moreira Ferreira, Shrishti Saxena, Bonnie Glanz, Hrishikesh A. Lokhande, Mariann Polgar-Turcsanyi, Rohit Bakshi, Howard L. Weiner, Tanuja Chitnis
Summary: The accuracy of biomarkers sNfL and sGFAP in detecting acute multiple sclerosis inflammation can be assessed through blood tests. A spot sNfL measurement greater than 23.0 pg/mL or a delta-change increase in sNfL of more than 30.8% from remission can predict CELs fairly well (with AUC values of 0.61 and 0.67, respectively).
MULTIPLE SCLEROSIS JOURNAL
(2023)
Meeting Abstract
Clinical Neurology
Sarah Conway, Maria Houtchens, Bonnie Glanz, Taylor J. Saraceno, Mariann Polgar-Turcsanyi, Patricia Gaitan Walsh, Emily Casady, Sasha Winston-Khan, Talia Feldman, Eunnindy Dells Sanon, Gauruv Bose, Shrishti Saxena, Aimee Loven, Choudhury Yusuf, Anu Paul, Rohit Bakshi, Shamik Bhattacharyya, Kristin Galetta, Tamara Kaplan, Christopher Severson, Tarun Singhal, Lynn Stazzone, Jonathan Zurawski, Brian Healy, Howard Weiner, Tanuja Chitnis
Meeting Abstract
Clinical Neurology
Vanessa F. Moreira Ferreira, Jonathan Zurawski, Brian C. Healy, Shrishti Saxena, Anu Paul, Fermisk Saleh, Yanqing Liu, Mariann Polgar-Turcsanyi, Harald Kropshofer, Howard Weiner, Tanuja Chitnis